JAZZ Jazz Pharmaceuticals plc

NEUTRAL Impact: 3/10 144
Horizon days Filed Jun 1, 2026 Processed 15d 11h ago SEC 0001628280-26-039499
Form 144 — notice of proposed sale of securities
Latest settled — T+5d ⚠ clustered
JAZZ ▲ +1.36% at T+5d
NEUTRAL call ✓ call won +1.36% · α vs SPY +4.32% · entry $226.12 → $229.19
Next anchor: T+20d in 13d
Currently $226.88 · +0.34% from $226.12 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
+2.13%
call +2.13% · α +2.85%
$230.93
settled 15d ago
T+5d
+1.36%
call +1.36% · α +4.32%
$229.19
settled 9d ago
T+20d
call — · α —
in 13d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, filed a Form 144 on June 1, 2026, indicating intent to sell 6,000 shares of common stock. At the filing date, the proposed sale value was approximately $1.41 million, representing a modest portion of his likely total holdings. The filing is a routine insider sale notice and does not signal material concern given the CEO's ongoing role and the relatively small size relative to market cap.

Actionable Insight

This is a routine insider sale notice from the CEO. The 6,000-share amount is small relative to his likely holdings and the company's market cap. No immediate trading action warranted; monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger sales.

Key Facts

  • Filer: Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals
  • Proposed sale: 6,000 shares of common stock
  • Estimated value at filing: ~$1,410,720 (based on $235.12/share)
  • Shares to be sold from stock options exercised on 03/05/2022
  • Broker: Merrill Lynch
  • Filing date: June 1, 2026; proposed sale date same day
  • Recent insider activity (30d): 4 sells totaling $3.1M

Financial Impact

Proposed sale of 6,000 shares valued at ~$1.41M, representing approximately 0.01% of Jazz's $14.8B market cap

dilution

Risk Factors

  • CEO selling could be misinterpreted as lack of confidence, though the small size mitigates this
  • If this is part of a 10b5-1 plan, the signal is further neutralized

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (24 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-039499
Document: 0001628280-26-039499-index.html0001628280-26-039499
Document: 0001628280-26-039499.txt0001628280-26-039499
14 reports for JAZZ
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for JAZZ — sortable, filterable
Type Now
Jun 8, 2026
8d ago
DEFA14A
NEUTRAL ★ 3/10
$229.19 $230.59▲ +0.61%▼ −1.80%$226.88 (−1.01%)
Jun 3, 2026
13d ago
Insider Cluster
BEARISH ★ 5/10
$239.17 $236.17▲ +1.26%▼ −1.30%$226.88 (+5.14%)
Jun 3, 2026
13d ago
Insider Cluster
NEUTRAL ★ 3/10
$240.06 $236.17▼ −1.62%▲ +0.93%$226.88 (−5.49%)
Jun 1, 2026
15d ago
144
NEUTRAL ★ 3/10
$226.12 $229.19▲ +1.36%▲ +4.32%$226.88 (+0.34%)
May 29, 2026
18d ago
8-K
NEUTRAL ★ 2/10
$231.19 $238.57▲ +3.19%▲ +5.94%$226.88 (−1.87%)
May 1, 2026
6w ago
144
NEUTRAL ★ 2/10
$202.51 $225.49▲ +11.35%▲ +9.00%$226.88 (+12.03%)
Apr 24, 2026
7w ago
10-K/A
NEUTRAL ★ 4/10
$200.31 $207.89▲ +3.78%▲ +3.38%$226.88 (+13.26%)
Apr 1, 2026
10w ago
144
NEUTRAL ★ 3/10
$186.73 $193.27▲ +3.50%▼ −0.12%$226.88 (+21.50%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $181.23▼ −4.11%▼ −2.13%$226.88 (+20.04%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $181.23▼ −4.11%▼ −2.13%$226.88 (+20.04%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 5h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access